VERU vs. NATR, SPRB, BLRX, LPTX, GALT, DBTX, ARAV, ANIX, ETON, and SPRO
Should you be buying Veru stock or one of its competitors? The main competitors of Veru include Nature's Sunshine Products (NATR), Spruce Biosciences (SPRB), BioLineRx (BLRX), Leap Therapeutics (LPTX), Galectin Therapeutics (GALT), Decibel Therapeutics (DBTX), Aravive (ARAV), Anixa Biosciences (ANIX), Eton Pharmaceuticals (ETON), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical preparations" industry.
Veru vs.
Nature's Sunshine Products (NASDAQ:NATR) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, community ranking, profitability, valuation and risk.
75.2% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 48.9% of Veru shares are owned by institutional investors. 5.4% of Nature's Sunshine Products shares are owned by insiders. Comparatively, 23.9% of Veru shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Veru received 106 more outperform votes than Nature's Sunshine Products when rated by MarketBeat users. Likewise, 69.21% of users gave Veru an outperform vote while only 62.80% of users gave Nature's Sunshine Products an outperform vote.
In the previous week, Nature's Sunshine Products' average media sentiment score of 1.91 beat Veru's score of 0.00 indicating that Nature's Sunshine Products is being referred to more favorably in the media.
Nature's Sunshine Products has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.
Nature's Sunshine Products currently has a consensus price target of $15.00, indicating a potential upside of 34.17%. Veru has a consensus price target of $13.67, indicating a potential upside of 1,280.47%. Given Veru's higher possible upside, analysts plainly believe Veru is more favorable than Nature's Sunshine Products.
Nature's Sunshine Products has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Veru has a beta of -0.22, indicating that its share price is 122% less volatile than the S&P 500.
Nature's Sunshine Products has a net margin of 0.81% compared to Veru's net margin of -652.36%. Nature's Sunshine Products' return on equity of 4.14% beat Veru's return on equity.
Summary
Nature's Sunshine Products beats Veru on 10 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
